Douglass Winthrop Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Douglass Winthrop Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-364	Closed	-$259K	–	292
2024 Q4	$259K	Buy	364 +150	+70%	+$126K	0.01%	264
2024 Q3	$225K	Hold	214	–	–	﹤0.01%	274
2024 Q2	$225K	Hold	214	–	–	﹤0.01%	264
2024 Q1	$206K	Buy	+214	New	+$203K	﹤0.01%	274
2022 Q3	–	Sell	-401	Closed	-$237K	–	255
2022 Q2	$237K	Buy	+401	New	+$261K	0.01%	230
2017 Q1	–	Sell	-775	Closed	-$284K	–	248
2016 Q4	$284K	Buy	775 +100	+15%	+$38K	0.02%	200
2016 Q3	$271K	Buy	675 +25	+4%	+$10K	0.02%	210
2016 Q2	$227K	Hold	650	–	–	0.02%	222
2016 Q1	$234K	Buy	650 +250	+63%	+$103K	0.02%	206
2015 Q4	$217K	Buy	+400	New	+$217K	0.02%	217
2015 Q1	–	Sell	-6,580	Closed	-$2.7M	–	268
2014 Q4	$2.7M	Buy	6,580 +30	+0.5%	+$11.8K	0.24%	62
2014 Q3	$2.36M	Hold	6,550	–	–	0.22%	62
2014 Q2	$1.85M	Hold	6,550	–	–	0.17%	66
2014 Q1	$1.97M	Hold	6,550	–	–	0.19%	63
2013 Q4	$1.8M	Hold	6,550	–	–	0.19%	65
2013 Q3	$2.05M	Hold	6,550	–	–	0.24%	60
2013 Q2	$1.47M	Buy	+6,550	New	+$1.53M	0.18%	68

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Douglass Winthrop Advisors's REGN Position: Q1 2025 in Review

Douglass Winthrop Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 364 shares — an estimated $259K sold.

Douglass Winthrop Advisors first reported a position in REGN in Q2 2013 and held it in 17 quarters. The position peaked at $2.7M in Q4 2014. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Douglass Winthrop Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Douglass Winthrop Advisors sold 364 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $259K.
Douglass Winthrop Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 17 quarters.
Douglass Winthrop Advisors's Regeneron Pharmaceuticals position peaked at $2.7M in Q4 2014.
1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Douglass Winthrop Advisors's 13F filing for Q1 2025, filed 14 May 2025.